Menu

Blog

Sep 2, 2023

Promising New Cancer Drug May Kill Cancer Cells with Minimal Side Effects

Posted by in categories: biotech/medical, chemistry

An exciting new cancer drug has recently entered into a phase 1 clinical trial supported by promising pre-clinical work. The drug, named AOH1996, targets a protein called proliferating cell nuclear antigen (PCNA), an essential player in the biological processes of DNA replication and repair. A team of researchers from City of Hope published the data describing how they identified and characterized AOH1996 in Cell Chemical Biology last week. Since then, the news of AOH1996 has appeared prominently in both scientific and mainstream media.

Using a rational drug design approach that develops drugs based on their specific biological targets, the researchers identified AOH1996. Lead researcher Linda Malkas named the drug after Anna Oliva Healey, a girl born in 1996 who succumbed to neuroblastoma at age 9.

In the laboratory, the researchers tested AOH1996 on over 70 different kinds of tumor cells as well as some healthy control cells. While the drug killed the cancer cells, it notably does not affect non-cancer cells, including blood cells and the cells lining the airway. This indicates AOH1996 as a selective drug that will suppress tumor growth but likely not cause adverse effects that can occur when a cancer drug damages healthy cells.

Comments are closed.